Oculis Holding AG (NASDAQ:OCS) Sees Large Growth in Short Interest

Oculis Holding AG (NASDAQ:OCS) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 20,800 shares, a growth of 20.9% from the July 31st total of 17,200 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average trading volume of 13,900 shares, the days-to-cover ratio is currently 1.5 days.

Oculis Price Performance

Shares of Oculis stock opened at $12.00 on Friday. Oculis has a 52 week low of $9.05 and a 52 week high of $14.47. The company has a quick ratio of 4.71, a current ratio of 5.27 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $11.69 and a 200 day moving average price of $11.87.

Analyst Ratings Changes

A number of brokerages recently weighed in on OCS. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Oculis in a research report on Wednesday. Robert W. Baird raised their price target on shares of Oculis from $35.00 to $37.00 and gave the company an “outperform” rating in a report on Tuesday, June 11th. Chardan Capital reiterated a “buy” rating and set a $30.00 price objective on shares of Oculis in a research note on Tuesday, June 11th. Finally, Bank of America lowered their target price on shares of Oculis from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, June 11th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $30.17.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oculis stock. Searle & CO. acquired a new position in Oculis Holding AG (NASDAQ:OCS) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,000 shares of the company’s stock, valued at approximately $112,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.